清瘤亮喉方对喉咽癌移植瘤生物学行为的影响及其机理研究
|
摘要
目的：研究清瘤亮喉方对喉咽癌移植瘤生物学行为的影响,并探讨其治疗或干预喉咽癌的作用机制。方法：1.建立梨状窝兔VX2瘤模型兔：VX2瘤细胞株荷瘤新西兰大白兔传代,以传代兔肿瘤组织块,制成肿瘤组织液,直达喉镜下接种于兔梨状窝。2.研究清瘤亮喉方对喉咽癌移植瘤生物学行为的影响：新西兰大白兔46只接种肿瘤后,随机分为空白组、对照组(氟尿嘧啶组)、治疗组(清瘤亮喉方组),除7只种植兔意外死亡外,余39只进入研究。随后观察其生存情况、影像学(CT)、解剖学、病理学(HE染色)及免疫组化(细胞周期调控因子cyclinB、cyclinD、CDK4及P27)研究。结果：服用清瘤亮喉方组(治疗组)及氟尿嘧啶组(对照组)的梨状窝VX2瘤兔的生存质量及存活时间明显优于空白组(p<0.05)；治疗组与对照组的梨状窝VX2瘤兔的肿瘤生长情况在解剖及影像学上与空白组存在显著差异(p<0.05)；治疗组与对照组的梨状窝VX2瘤兔的肿瘤生长情况在病理学上与空白组存在显著差异(p<0.05)；治疗组与对照组、空白组的梨状窝VX2瘤兔的肿瘤生长情况在免疫组化研究上存在显著差异(p<0.05)。结论：1.清瘤亮喉方能有效改善梨状窝VX2瘤兔的生存质量,延长肿瘤兔的生命。2.清瘤亮喉方能干预喉咽癌移植瘤的生长,其机制可能是通过诱导肿瘤细胞凋亡。3.清瘤亮喉方对喉咽癌的治疗作用,体现了中药对机体免疫功能的调节。
Objective:To Study of the effects on the biological behavior of the VX2 pyriformsinuscarcinoma(PSC) model with Qing Liu Ling Hou prescription; and to study the mechanism of the therapeutic effect with it.Methods:1. Establishment of Rabbit VX2 pyriformsinuscarcinoma model:To establish a rabbit VX2 hypolaryngocarcinom (HPC) model and observe it's growth. After anesthesia,tumor tissues from the VX2 cancer New Zealand rabbit was implanted to the rabbits'groin to passage.Then tumor tissues from the passaged- rabbits,was made tumor tissue mass suspension, and the suspension was injected into rabbit's pyriform sinus guided by rigid bronchoscope,2. The study of the efects on the biological behavior of the VX2 HPC model with Qing Liu Ling Hou prescription:46 rabbits of VX2 PSC model were divided into three groups in random:blank groups,cntrol groups of 5-F(FLUOROURACIL) and Chinese heb groups (Qing Liu Ling Hou prescription).7of the total 39 rabbits in the study died by accident. Therefore,the growth and metastatic character were observed by anatomy,CT and pathology. Immunohistochemistry staining by specific monoclonal anti-p27/Kipl protein,anti-cyclin D1 protein, anti-cyclin B protein and anti-CDK4 protein was performed using the S-P method..Results:1. The control groups and treatment groups in the living quality and duration were marked different than the blank groups.2. The control groups and treatment groups in anatomy and intervertebral were differently expressed as compared with those in blank groups. The control groups and treatment groups were significantly different with the blank groups in pathology. In immunology,the control groups were were significantly different with treatment groups, and the blank groups were significantly different with the control groups.Conclusion:1.To Qing Liu Ling Hou prescription; it can effectively improve the living quality, prolong the lifespan of the cancer rabbit.2. Qing Liu Ling Hou prescription can promote tumor-cells apoptosis in the VX2 PSC model by interventing expression of tumor-cells potentiality.3.The therapeutic principle of Qing Liu Ling Hou prescription may be based on promoting or inhibiting the expression of cellular potentiality,so it embodied the adjustion of the traditional chinese medicine on the body's immune function.
Objective:To Study of the effects on the biological behavior of the VX2 pyriformsinuscarcinoma(PSC) model with Qing Liu Ling Hou prescription; and to study the mechanism of the therapeutic effect with it.Methods:1. Establishment of Rabbit VX2 pyriformsinuscarcinoma model:To establish a rabbit VX2 hypolaryngocarcinom (HPC) model and observe it's growth. After anesthesia,tumor tissues from the VX2 cancer New Zealand rabbit was implanted to the rabbits'groin to passage.Then tumor tissues from the passaged- rabbits,was made tumor tissue mass suspension, and the suspension was injected into rabbit's pyriform sinus guided by rigid bronchoscope,2. The study of the efects on the biological behavior of the VX2 HPC model with Qing Liu Ling Hou prescription:46 rabbits of VX2 PSC model were divided into three groups in random:blank groups,cntrol groups of 5-F(FLUOROURACIL) and Chinese heb groups (Qing Liu Ling Hou prescription).7of the total 39 rabbits in the study died by accident. Therefore,the growth and metastatic character were observed by anatomy,CT and pathology. Immunohistochemistry staining by specific monoclonal anti-p27/Kipl protein,anti-cyclin D1 protein, anti-cyclin B protein and anti-CDK4 protein was performed using the S-P method..Results:1. The control groups and treatment groups in the living quality and duration were marked different than the blank groups.2. The control groups and treatment groups in anatomy and intervertebral were differently expressed as compared with those in blank groups. The control groups and treatment groups were significantly different with the blank groups in pathology. In immunology,the control groups were were significantly different with treatment groups, and the blank groups were significantly different with the control groups.Conclusion:1.To Qing Liu Ling Hou prescription; it can effectively improve the living quality, prolong the lifespan of the cancer rabbit.2. Qing Liu Ling Hou prescription can promote tumor-cells apoptosis in the VX2 PSC model by interventing expression of tumor-cells potentiality.3.The therapeutic principle of Qing Liu Ling Hou prescription may be based on promoting or inhibiting the expression of cellular potentiality,so it embodied the adjustion of the traditional chinese medicine on the body's immune function.
引文
[1]吴元庆,樊贤超,邓毅,徐进敬.螺旋CT检查在喉癌及喉咽癌颈部淋巴结转移中的诊断价值.黑龙江医学,2010,34(10)：761-763
[2]Dunne AA, Schmidt A, Kuropkat C, et al. The auricular VX2 carcinoma aa-an animal model for sentinel node concep t. In V ivo 2003,17: 457-461
[3]Kim SH, Choi D, Lim HK, etal.Deteetion of hepatic VX2 carcinomas with ferucarbotran—enhanced magnetirc resonance imaging in rabbits:ComParison of nine Puls Sequences.Eur J Radiol,2006,59(3):413—423
[4]ShomuraY, Saito Y, Minami K, et al.A new method for establishing an intrap-ulmonary tumor in the rabbit[J].JpJ Thorae Cardiovasc surg,2003,51 (8):337 —343
[5]Stewart EE, Chen X, Hadway J et al.Correlation between hepatic tumor blood flow and glucose utilization in a rabbit liver tumo rmodel.Radiology,2006, 239(3):740-750
[6]Dunne AA, Mandic R, Ramaswamy A, et al. Lymphogenic metastatic sp read of auricular VX2 carcinoma in N ew Zealand white rabbits. Anticancer Res,2002, 22 (6A):3273-3279.
[7]van Es RJ, Dullens HF, van der B ilt A, et al. Evaluation of the VX2 rabbit auricle carcinoma as a model for head and neck cancer in humans. J Maxillofac Surg,2000,8:300-307.
[8]Sapundzhiev N, DunneAA, Ramaswamy A, et al. The auricular VX2 carcinoma:feasibility of complete tumor resection Anticancer Res,2005, 25(6B):4209-14.
[9]田军,廖贵清,刘海潮,李传真,李清,王敬旭,杜日昌,张同韩.兔VX_2舌鳞癌移植瘤模型3种建立方法的比较.华西口腔医学杂志,2009,27(03)：326-329
[10]周军,龙清云,刘骏方,胡金香,刘真,乐涛.兔子宫VX2肿瘤模型的制作及其影像学表现.临床放射学杂志,2009,28(03)：412-414
[11]黄江琼,等.兔VX2鼻咽移植癌的PET—CT与病理结果对照研究.中华肿瘤防治 杂志2008年15卷(22)：1698-1702
[12]袁友红,肖恩华,刘建滨,等.兔肝VXZ瘤MR扩散加权成像与病理的动态对照研究[J].中华放射学杂志,2007,41(1)：81-85.
[13]刘险峰,等.兔VX2细胞系的建立及其生物学特性观察,中华病理学杂志,200534(10)：661-663
[14]唐平章,屠规益.下咽癌的手术方式和综合治疗.中华耳鼻咽喉科杂志,1992,27：17-19.
[15]Tang PZ,Wu XX, Tu GY.The Surgical management for carcinomas of thhypopharynx::an analysis of 254 cases.Chin J Otorhinolarynxgol,199732:83-88.
[16]Mariette C, Fabre S, Balon JM,et al. Reconstruction after total circula pharyngolaryngectomy:comparison between gastric interposition and frejejunal flap. Ann Chir,2002,127:431-438.
[17]Ullah R, Bailie N, Kinsella J,et al. Pharyngo-laryngo-oesophagectom and gastric pull-up for post-cricoid and cervical oesophageal squamou cell carcinoma. J Laryngol Otol,2002,116:826-830.
[18]张宗敏等.下咽鳞癌不同治疗方案的临床分析,中华肿瘤杂志,2005,27(1)：48-51
[19]唐平章等.喉咽癌的治疗.中国医学文摘耳鼻咽喉科学,2007,22(6)：314-315
[20]高顺禹,王继琛,蒋学祥,等.单期增强CT扫描在下咽癌和喉癌检查中的作用[J].实用放射学杂志,2005,21(8)：804-808.
[21]Buckley J G, MacLennan K-Cervical nodemetastases in laryngealand hypopharyngeal cancer:a prospective analysis of prevalence and distribution[J]·Head-Neck,2000,22:380-385·
[22]李焕荣,李秀荣.中医药抑制肿瘤血管生成抗肿瘤转移的可行性探讨[J].中西医结合学报,2007,5(4)：378-382
[23]陈万军,王天铎.细胞周期蛋白循环素在下咽癌生物学行为中的意义[J].临床耳鼻咽喉科杂志,2005,19(6)：250-252
[24]Jiang C, Ye D, Qiu W,et al. Response of lymphocyte subsets and cytokines to Shenyang prescription in Sprague-Dawley rats with tongue squamous cell carcinomas induced by 4NQO. BMC Cancer.2007,5,7:40.
[25]陈万军等.CDK与下咽癌病变的相关性及其生物学行为的初步研究[J].山东大学 基础医学学院学报,2005,19(6)：149-152
[26]牛韵韵等.食管鳞癌组织中P16, cyclinD1、CDK4的表达[J].河南医科大学学报,2001,36(5)：539-541
[27]Youyi Dong, Li Sui, Katsuyoshi Sugimoto, et al.C yclinD1、CDK4 complex, apissible, critical factor for cell proliferation and prognosis in laryngeal squamous cell carcinomas [J], Int J Cancer (Pred.Oncol),2001,95 (4):209-215
[28]陈万军,李梅,王兴武,等.细胞周期调控因子与下咽癌生物学行为相关性初步研究[J].中国肿瘤临床,2007,34(1)：26-29
[29]赵辉；刘勇智.P27和CyclinD1在喉鳞癌组织中的表达及意义[J].内蒙古医学杂志,2010,42(1)：45-46
[30]Namazie A,Alavi S,Olufunmilayo I,et al.Cyclin D1 Amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosisin head and neck tumors[J].Laryngoscope,2002,112(3):472-481
[31]Akervall JA,Michalides RJ,Mineta H,et al.Amplification of cyclin dl in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin dl overexpression[J].Cancer,1997,79(2):380-389
[32]Kyomoto R,Kumazawa H,Toda Y,et al.Cyclin-Dl-gene amplification is a more potent prognostic factor than its protein overexpression in human head and neck squamous cell carcinoma[J].Int J Cancer,1997,74(6):576-581
[33]Pruneri G,Pignataro L.Carboni N,et al.Clinical relevance of expression of the CIP/KIP cell-oycle inhibitors p21 and p27 in laryngeal cancer[J].J Clin Oncol,1999,17(10):3150-3159
[34]陈万军,王天铎.鼠抗人单克隆抗体P27kip1及细胞周期素D1与下咽癌临床关系的研究[J].中华肿瘤杂志,2004,26(6)：358-359
[35]吴晓华,徐小虎,沈忠英,等.细胞周期蛋白Cyclin D1、CDK4在食道癌中的表达及其意义[J].癌症,2000,19(1)：23-26
[36]Matsumoto M,Furihata M,Ishikawa T,et al.Comparison ofderegulated expression of Cyclin D1 and Cyclin E with that of cyclin-dependent kinase 4(CDK4)and CDK2 in human oesophageal squamous cell carcinoma[J].Br J Cancer,1999,80(1-2):256-261
[37]Dong YY,Sui L,Sugimoto K,et al.Cyclin D1-CDK4 complex,a possible critical factor for cell proliferation and prognosis in laryngeal squamous cell carcinomas[J]. Int Cancer,2001,95(4):209-15
[38]王建功,胡万宁PPN/MG61、CyclinB2在甲状腺肿瘤组织及外周血中的表达[J],山东医药,2009,49(16)：76-77
[39]Hwang A, Muschel R J. Radiation and the G2 Phase of the Cell Cycle. Radiat. Res., 1998.150(Suppl):52
[40]Datta R, Hass R, Gunji H, et al. Down-regulation of Cell Cycle Control Genes by Ionizing Radiation. Cell Growth Differ.,1992.3:637
[41]王永钦.中医耳鼻咽喉口腔科学,北京：人民卫生出版社,2001,863-870
[42]王德鉴.中医耳鼻咽喉口腔科学,北京：人民卫生出版社,1994,530-535
[43]张雅琨,陈仁寿.鼻咽癌放疗毒副反应的中医药治疗进展.国医论坛2007,22(3)：54-56
[44]白建平,徐凯,刘伟胜.中医药治疗放疗咽粘膜反应回顾.实用中西医结合临床.2005,5(4)：92-93
[45]王贤文,田道法.鼻咽癌高危人群的中医药防治研究进展。中国中西医结合耳鼻咽喉科杂志.2004,12(4)：223-225
[46]赵立民,曾桂凤,孙秀霞.辨证论治配合心理干预对中晚期喉癌患者生存质量的影响.辽宁中医杂志.2006,33(8)：913-914
[47]邱宝珊,王士贞,钟艳萍.鼻咽癌急性放疗反应的中医辨证论治。中华实用中西医杂志。2003(16)：433-434
[48]刘书静,田道法,李车芳.鼻咽癌中医辨证分型与预后相关性基因活性表达关系的初步研究.中国中西医结合耳鼻咽喉科杂志,2005,13(1)：1-3
[49]焦红军.党参的药理作用及其临床应用[J].临床医学,2005,25(4)：92
[50]韩桂茹,贺秀芬,杨建红,等.党参化学成分的研究.中国中药杂志,1990；15(2)：105.
[51]余伯阳,徐国钧,金蓉鸾,等.麦冬类中药的药源调查和商品鉴定.中国药科大学学报,1991；22(5)：286.
[52]蒋风荣,张旭,范俊等.麦冬药理作用研究进展[J].中医药学刊,2006,24(2)：236-237
[53]陈雪霞,李民,张旭.麦冬药血清抗血管内皮细胞损伤的机制研究[J].国医论坛,2007,22(1)：38-39
[54]汤军,黄琦,徐志瑛,等.麦冬多糖的免疫活性研究[J].中国中医基础医学杂志,1998,4(9)：44
[55]舒琦瑾,吴良村.新加沙参麦冬汤抗肿瘤的实验研究[J].中国中医基础医学杂志,2002,8(4)：34
[56]彭丽娟,鲍扬漪,朱晓梅等SM-EDTMP与麦冬注射液联合治疗骨转移癌[J].安徽医科大学学报,1999,10(5)：383
[57]陶站华,白书阁,白晶.麦冬对D半乳糖衰老模型大鼠的抗衰老作用研究[J].黑龙江医药科学,1999,22(4)：36
[58]郭晶,陈非,李丽华,等.中药麦冬对D半乳糖衰老模型大鼠的血液流变性的影响[J].中国微循环,2002,6(4)：246
[59]刘训红,阚毓铭.太子参研究概述[J]时珍国医国药,2000,11(12)：1131-1132
[60]刘维俊,黄光才,叶小青,等.太子参胶囊的药效学研究[J]_中药新药与临床药理,1994,5(3)：51,58.
[61]黄国城,施少捷,郑强.太子参和香菇抗衰老效应的实验研究[J].福建预防医学杂志,1994,3(2)：68.
[62]徐宝林,孙健,杨锋,等.补益药对细胞免疫功能影响的实验研究[J].浙江中医杂志,1996,(5)：219-220.
[63]王家葵,郑军,沈映君,等.太子参总提取物对环磷酰胺处理动物免疫功能和胸腺、脾脏核酸含量的影响[J].中药药理与临床,1996,12(6)：16-18.
[64]王吉吉星,徐绥绪,张国刚,等.太子参化学成分的研究(Ⅳ)[J].中国药物化学杂志,1992,2(3)：65-67.
[65]黄晓洁,颜耀东,杨正娟,那爱华.沙参对免疫功能的影响,沈阳药学院学报,1991,8(3)：204-207
[66]徐宝林,孙健,杨锋,王锦云.补益药对细胞免疫功能影响的实验研究[J]浙江中医杂志,1996,(05)：219-220
[67]郭勇,程晓磊.石斛在恶性肿瘤治疗中的作用[J].浙江中西医结合杂志,2007,17(7)： 454-455
[68]陈云珠,钟鸣.射干药理作用的现代研究进展,中国中医药现代远程教育,2006,4(10)： 27-29
[69]王昊,杨凤琴.10种中药时致病性浅部真菌的抑菌实脸研究.中医杂志,1997,38(7)：431-432
[70]刘春平,王凤荣,南国荣等.中药射干提取物时皮肤碑菌抑菌作用研究中华皮肤科杂志,1998,31(5)：310-311
[71]Oh KB, Kang H, Matsuoka H. Detection of antifungal activity in Belamcanda chinensis by a single-cell bioassay method and isolation of its active compound tectorigenin, Biosci Biotechnol Biochem,2001,65(4):939-942
[72]于军,徐丽华,王云等.射干和马齿览时46株绿脓杆菌体外抑菌试脸的研究.白求恩医科大学学报,2001,27(2)：130-131.
[73]娜杨,孔红,李宜平等.射干的抗病毒实脸研究.中草药,2004,35(3)：306-308
[74]Yamaki K, Kim DH, Ryu N.et.al.Effects of naturally occurring isoflavones on prostaglandin E2 production.Plants Med,2002,68(2):97-100
[75]Ahn KS, Noh EJ, Cha KH.et.al.lnhibitory effects of Irigenin from the rhizomes of & lamcanda chinensis on nitricoxide and prostaglandin E(2) production in murine macrophage RAW 264.7 ceIIs.Life Sci,2006,78(20);2336-2342
[76]Jung SH, Lee YS, Lim SS.et.al.Antioxidant activities of isoflavones from the rhizomes of & lamcanda chinensis on carbon tetrachloride-induced hepatic injury in rats. Arch Pharm Res,2004; 27(2); 184-188
[77]秦民坚,吉文亮,刘俊等.射干中异黄酮成分清除自由基的作用.中草药,2003,34(7)；640
[78]钟鸣,关旭俊,黄炳盛等.中药射干现代研究进展.中药材,2001,24(12)： 904-907
[79]Theien P, seseke F, Ringent RN.et.al.Pharmacological potential of phytoestrogens in the treatment of prostate cancer. Urologe A,2006,45(2):195-201
[80]车景超,辛宁,丰杰.白花蛇舌草药理研究进展安徽农业科学,Journalof Anhui Agricultural Sciences,200735 (20):6162-6167
[81]谭宁华,王双明,杨亚滨等.白花蛇舌草的抗肿瘤活性和初步化学研究[J].天然产物研究与开发,2002,14(5)：33—36.
[82]袁志诚,李巧玉,陈波,等.白花蛇舌草在裸鼠胶质瘤间质化疗的实验研究[J].江苏医药杂志,2003,29(11)：808—810.
[83]于春艳,李薇,刘玉和,等.白花蛇舌草体外对人体肝癌多药耐药细胞Bel-7402 抗肿瘤活性的研究[J].北华大学学报,2004,5(3)：221—223.
[84]于春艳,李薇,刘玉和,等.白花蛇舌草提取物体外抗肿瘤作用及机制研究[J].北华大学学报,2004,5(5)：412—416.
[85]王宇翎,张艳,方明,等.白花蛇舌草总黄酮的免疫调节作用[J].中国药理学通报,2005,21(4)：444—447.
[86]王宇翎,张艳,方明,等.白花蛇舌草总黄酮的抗炎及抗菌作用[J].中国药理学通报,2005,21(3)：348—350.
[87]王桂英,李振彬,石建喜,等.白花蛇舌草对吲哚美辛所致大鼠胃粘膜损伤的保护作用[J].河北中医,2001,23(1)：70—71.
[88]黄景玉,李建平,姜祖光,等.康莱特加白花蛇舌草注射液联合介入治疗晚期原发性肝癌的近期疗效观察[J].实用肿瘤杂志,2002,17(5)：352—353.
[89]唐立明,汪金华,周洪进.静滴白花蛇舌草注射液治疗中晚期食道癌106例临床观察[J].海南医学,2003,14(2)：75.
[90]张琼,张晓亚,庞秀华.白花蛇舌草注射液联合EP方案与单纯EP方案治疗非小细胞肺癌的疗效比较[J].河南职工医学院学报,2001,13(1)：40—41.
[91]李焕荣,李秀荣.中医药抑制肿瘤血管生成抗肿瘤转移的可行性探讨[J]。中西医结合学报,2007,5(4)：378-382
[92]赵旭,李福才,李英慧.等.P53基因突变和STK15基因过度表达与喉癌发生的关系.中华肿瘤杂志.2005,3,27(3)：134-137
[1]Michalides R, van Veelen N, Hart A, et al.Overexpression of cyclinD1 correlates with recurrence in group of forty-seven operable squamous cell carcinomas of the head and nech.Cancer Res,1995,55:975-978.
[2]于锋,董玉礼,祖志将等,喉咽癌手术及综合治疗的临床资料分析,中华耳鼻咽喉科杂志,2003,38(4)：295-299
[3]Tang RZ, Wu XX, Tu GY.The surgical management of carcinoma of the hypopharynx: An analysis of 254 cases. China J Otorhinolaryngol,1997,32 Suppl(Eng):83-88.
[4]屠规益,唐平章,贺永东,等.应用舌骨肌瓣修复部分喉术后缺损.中华耳鼻咽喉科杂志,1996,31：39-42.
[5]屠规益.头颈肿瘤外科中的实证医学.中华耳鼻咽喉科杂志,2000,35：327-330.
[6]郭智,朱永学,嵇庆海,喉咽癌的综合治疗,中国医学文摘耳鼻咽喉科学,2006,21 (6)：363-365
[7]韩德民,于振坤,黄志刚,等.会厌在喉部分切除喉功能重建术中的应用.中华耳鼻咽喉科杂志,2000,35：42-44.
[8]唐平章,屠规益,祁永发,等.喉近全切除术的扩大适应证.中华耳鼻咽喉科杂志,1998,33：175-177.
[9]于锋,董玉礼,韩跃峰,等.喉环上部分切除喉腔成形术.中华耳鼻咽喉科杂志,2001,36：213-215.
[10]Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol,2003,21:320-326.
[11]Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med,2004,350:1937-1944.
[12]Stenson KM, Haraf DJ, Pelzer H, et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy:the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg,2000,126:950-956.
[13]Argiris A, Stenson KM, Brockstein BE, et al. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head andneck cancer. Head Neck,2004,26447-455.
[14]Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer:preliminary results of a European Organization for Research and Treatment of Cancer phase Ⅲ trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst,1996,88:890-899.
[15]Lefebvre JL, Chevalier D, Luboinski B, et al. Is laryngeal preservation(LP)with induction chemotherapy(ICT)safe in the treatment of hypopharyngeal SCC? Final results of the phaseⅢEORTC 24891 trial. J Clin Oncol, ASCO Annual Meeting Proceedings(Post-Meeting Edition),2004,22(14S):Abstr 5531.
[16]Hitt R, Lopez-Pousa A, Rodriguez M, et al. Phaselll study comparing cisplatin and 5 fluorouracil versus cisplatin 5-fluorouracil and paclitaxel asinduction therapy in locally advanced head and neck cancer. Proc Am Soc Clin Oncol,2003,22.
[17]Katori H, Tsukuda M, Ishitoya J, et al. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil(TPF)followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Clin Oncol(RColl Radiol),2005:17:148-152.
[18]Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma:a University of Pennsylvania Phase Ⅱ Trial. J Clin Oncol.2002,20: 3964-3971.
[19]Bonner JA, Giralt J, Harari PM, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck:A phase Ⅲ study of high dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol,2004,22:7078.
[20]Soulieres D, Senzer NN, Vokes EE, et al. Multi center phase Ⅱ study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, inpatients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol, 2004,22:77-85.
[21].Hitt R, Grau J, Lopez-Pousa A, et al. Phase Ⅱ/Ⅲ trial of induction chemotherapy(ICT)with cisplatin/5-fluorouracil(PF)vs. docetaxel(T)plus PF(TPF)followed by chemoradiotherapy(CRT)vs. CRT for unresectable locally advanced head and neck cancer(LAHNC). Proc Am Soc Clin Oncol,2003,22: 496
[22]Ogura JH. Partial laryngopharyngectomy and neck dissection for pyrifom sinus cancer.Laryngoscope,1960,70:1399-1417.
[23]Dumich PS, Pearson BW, Weiland LH. Suitability of near-total laryngopharyngectomy in piriform carcinoma. Arch Otolaryngol,1984 110:664-669.
[24]Hirano M, Kurita S, Tanaka H. Histopathologic study of carcifma ofthe hypopharynx:implications for conservation surgery.Ann Otol Rhinol Laryngol, 1987,96:625-629.
[25]黄建民,栾信庸,潘新良,等.梨状窝内侧壁癌切除与喉功能保留.中华耳鼻咽喉 科杂志,2001,36：254-257.
[26]Harrison DF. Thyroid gland in the management of laryngopharyngeal cancer.Arch Otolaryngol,1973,97:301-302.
[27]Pillsbury HC 3rd, Clark M.A rational for therapy of the NO neck.Laryngoscope, 1997,107:1294-1315.
[28]Spiro RH, Gall O, Shah JP. Selective jugular node dissection in patients with squamous carcinoma of the larynx or pharynx.Am J Surg,1993,166:399-340.
[29]李晓明,宋琦,喉癌喉咽癌的辅助与综合治疗,中国耳鼻咽喉头颈外科,2009 16(10)：555-557
[30]金晶,高黎,徐国镇,等.单纯放疗或单纯手术治疗早期声门型喉癌.中华放射肿瘤学杂志,2005,14：1-5.
[31]Menenhall WM. T3-4 squamous cell carcinoma of the larynxtreated with radiation therapy alone. Semin Radiat Oncol,1998,8:262-269.
[32]Jorgensen K, Godballe C, Hansen O, et al. Cancer of the larynx:treatment results after primary radiotherapy with salvage surgery in a series of 1005 patients. Acta Oncol,2002,41:69-76.
[33]陈建超,王朝晖,李彬,张兵,王少新,李超.保留喉功能喉咽癌的综合治疗.中国耳鼻咽喉头颈外科,2005,12(11)：718-720
[2]Dunne AA, Schmidt A, Kuropkat C, et al. The auricular VX2 carcinoma aa-an animal model for sentinel node concep t. In V ivo 2003,17: 457-461
[3]Kim SH, Choi D, Lim HK, etal.Deteetion of hepatic VX2 carcinomas with ferucarbotran—enhanced magnetirc resonance imaging in rabbits:ComParison of nine Puls Sequences.Eur J Radiol,2006,59(3):413—423
[4]ShomuraY, Saito Y, Minami K, et al.A new method for establishing an intrap-ulmonary tumor in the rabbit[J].JpJ Thorae Cardiovasc surg,2003,51 (8):337 —343
[5]Stewart EE, Chen X, Hadway J et al.Correlation between hepatic tumor blood flow and glucose utilization in a rabbit liver tumo rmodel.Radiology,2006, 239(3):740-750
[6]Dunne AA, Mandic R, Ramaswamy A, et al. Lymphogenic metastatic sp read of auricular VX2 carcinoma in N ew Zealand white rabbits. Anticancer Res,2002, 22 (6A):3273-3279.
[7]van Es RJ, Dullens HF, van der B ilt A, et al. Evaluation of the VX2 rabbit auricle carcinoma as a model for head and neck cancer in humans. J Maxillofac Surg,2000,8:300-307.
[8]Sapundzhiev N, DunneAA, Ramaswamy A, et al. The auricular VX2 carcinoma:feasibility of complete tumor resection Anticancer Res,2005, 25(6B):4209-14.
[9]田军,廖贵清,刘海潮,李传真,李清,王敬旭,杜日昌,张同韩.兔VX_2舌鳞癌移植瘤模型3种建立方法的比较.华西口腔医学杂志,2009,27(03)：326-329
[10]周军,龙清云,刘骏方,胡金香,刘真,乐涛.兔子宫VX2肿瘤模型的制作及其影像学表现.临床放射学杂志,2009,28(03)：412-414
[11]黄江琼,等.兔VX2鼻咽移植癌的PET—CT与病理结果对照研究.中华肿瘤防治 杂志2008年15卷(22)：1698-1702
[12]袁友红,肖恩华,刘建滨,等.兔肝VXZ瘤MR扩散加权成像与病理的动态对照研究[J].中华放射学杂志,2007,41(1)：81-85.
[13]刘险峰,等.兔VX2细胞系的建立及其生物学特性观察,中华病理学杂志,200534(10)：661-663
[14]唐平章,屠规益.下咽癌的手术方式和综合治疗.中华耳鼻咽喉科杂志,1992,27：17-19.
[15]Tang PZ,Wu XX, Tu GY.The Surgical management for carcinomas of thhypopharynx::an analysis of 254 cases.Chin J Otorhinolarynxgol,199732:83-88.
[16]Mariette C, Fabre S, Balon JM,et al. Reconstruction after total circula pharyngolaryngectomy:comparison between gastric interposition and frejejunal flap. Ann Chir,2002,127:431-438.
[17]Ullah R, Bailie N, Kinsella J,et al. Pharyngo-laryngo-oesophagectom and gastric pull-up for post-cricoid and cervical oesophageal squamou cell carcinoma. J Laryngol Otol,2002,116:826-830.
[18]张宗敏等.下咽鳞癌不同治疗方案的临床分析,中华肿瘤杂志,2005,27(1)：48-51
[19]唐平章等.喉咽癌的治疗.中国医学文摘耳鼻咽喉科学,2007,22(6)：314-315
[20]高顺禹,王继琛,蒋学祥,等.单期增强CT扫描在下咽癌和喉癌检查中的作用[J].实用放射学杂志,2005,21(8)：804-808.
[21]Buckley J G, MacLennan K-Cervical nodemetastases in laryngealand hypopharyngeal cancer:a prospective analysis of prevalence and distribution[J]·Head-Neck,2000,22:380-385·
[22]李焕荣,李秀荣.中医药抑制肿瘤血管生成抗肿瘤转移的可行性探讨[J].中西医结合学报,2007,5(4)：378-382
[23]陈万军,王天铎.细胞周期蛋白循环素在下咽癌生物学行为中的意义[J].临床耳鼻咽喉科杂志,2005,19(6)：250-252
[24]Jiang C, Ye D, Qiu W,et al. Response of lymphocyte subsets and cytokines to Shenyang prescription in Sprague-Dawley rats with tongue squamous cell carcinomas induced by 4NQO. BMC Cancer.2007,5,7:40.
[25]陈万军等.CDK与下咽癌病变的相关性及其生物学行为的初步研究[J].山东大学 基础医学学院学报,2005,19(6)：149-152
[26]牛韵韵等.食管鳞癌组织中P16, cyclinD1、CDK4的表达[J].河南医科大学学报,2001,36(5)：539-541
[27]Youyi Dong, Li Sui, Katsuyoshi Sugimoto, et al.C yclinD1、CDK4 complex, apissible, critical factor for cell proliferation and prognosis in laryngeal squamous cell carcinomas [J], Int J Cancer (Pred.Oncol),2001,95 (4):209-215
[28]陈万军,李梅,王兴武,等.细胞周期调控因子与下咽癌生物学行为相关性初步研究[J].中国肿瘤临床,2007,34(1)：26-29
[29]赵辉；刘勇智.P27和CyclinD1在喉鳞癌组织中的表达及意义[J].内蒙古医学杂志,2010,42(1)：45-46
[30]Namazie A,Alavi S,Olufunmilayo I,et al.Cyclin D1 Amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosisin head and neck tumors[J].Laryngoscope,2002,112(3):472-481
[31]Akervall JA,Michalides RJ,Mineta H,et al.Amplification of cyclin dl in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin dl overexpression[J].Cancer,1997,79(2):380-389
[32]Kyomoto R,Kumazawa H,Toda Y,et al.Cyclin-Dl-gene amplification is a more potent prognostic factor than its protein overexpression in human head and neck squamous cell carcinoma[J].Int J Cancer,1997,74(6):576-581
[33]Pruneri G,Pignataro L.Carboni N,et al.Clinical relevance of expression of the CIP/KIP cell-oycle inhibitors p21 and p27 in laryngeal cancer[J].J Clin Oncol,1999,17(10):3150-3159
[34]陈万军,王天铎.鼠抗人单克隆抗体P27kip1及细胞周期素D1与下咽癌临床关系的研究[J].中华肿瘤杂志,2004,26(6)：358-359
[35]吴晓华,徐小虎,沈忠英,等.细胞周期蛋白Cyclin D1、CDK4在食道癌中的表达及其意义[J].癌症,2000,19(1)：23-26
[36]Matsumoto M,Furihata M,Ishikawa T,et al.Comparison ofderegulated expression of Cyclin D1 and Cyclin E with that of cyclin-dependent kinase 4(CDK4)and CDK2 in human oesophageal squamous cell carcinoma[J].Br J Cancer,1999,80(1-2):256-261
[37]Dong YY,Sui L,Sugimoto K,et al.Cyclin D1-CDK4 complex,a possible critical factor for cell proliferation and prognosis in laryngeal squamous cell carcinomas[J]. Int Cancer,2001,95(4):209-15
[38]王建功,胡万宁PPN/MG61、CyclinB2在甲状腺肿瘤组织及外周血中的表达[J],山东医药,2009,49(16)：76-77
[39]Hwang A, Muschel R J. Radiation and the G2 Phase of the Cell Cycle. Radiat. Res., 1998.150(Suppl):52
[40]Datta R, Hass R, Gunji H, et al. Down-regulation of Cell Cycle Control Genes by Ionizing Radiation. Cell Growth Differ.,1992.3:637
[41]王永钦.中医耳鼻咽喉口腔科学,北京：人民卫生出版社,2001,863-870
[42]王德鉴.中医耳鼻咽喉口腔科学,北京：人民卫生出版社,1994,530-535
[43]张雅琨,陈仁寿.鼻咽癌放疗毒副反应的中医药治疗进展.国医论坛2007,22(3)：54-56
[44]白建平,徐凯,刘伟胜.中医药治疗放疗咽粘膜反应回顾.实用中西医结合临床.2005,5(4)：92-93
[45]王贤文,田道法.鼻咽癌高危人群的中医药防治研究进展。中国中西医结合耳鼻咽喉科杂志.2004,12(4)：223-225
[46]赵立民,曾桂凤,孙秀霞.辨证论治配合心理干预对中晚期喉癌患者生存质量的影响.辽宁中医杂志.2006,33(8)：913-914
[47]邱宝珊,王士贞,钟艳萍.鼻咽癌急性放疗反应的中医辨证论治。中华实用中西医杂志。2003(16)：433-434
[48]刘书静,田道法,李车芳.鼻咽癌中医辨证分型与预后相关性基因活性表达关系的初步研究.中国中西医结合耳鼻咽喉科杂志,2005,13(1)：1-3
[49]焦红军.党参的药理作用及其临床应用[J].临床医学,2005,25(4)：92
[50]韩桂茹,贺秀芬,杨建红,等.党参化学成分的研究.中国中药杂志,1990；15(2)：105.
[51]余伯阳,徐国钧,金蓉鸾,等.麦冬类中药的药源调查和商品鉴定.中国药科大学学报,1991；22(5)：286.
[52]蒋风荣,张旭,范俊等.麦冬药理作用研究进展[J].中医药学刊,2006,24(2)：236-237
[53]陈雪霞,李民,张旭.麦冬药血清抗血管内皮细胞损伤的机制研究[J].国医论坛,2007,22(1)：38-39
[54]汤军,黄琦,徐志瑛,等.麦冬多糖的免疫活性研究[J].中国中医基础医学杂志,1998,4(9)：44
[55]舒琦瑾,吴良村.新加沙参麦冬汤抗肿瘤的实验研究[J].中国中医基础医学杂志,2002,8(4)：34
[56]彭丽娟,鲍扬漪,朱晓梅等SM-EDTMP与麦冬注射液联合治疗骨转移癌[J].安徽医科大学学报,1999,10(5)：383
[57]陶站华,白书阁,白晶.麦冬对D半乳糖衰老模型大鼠的抗衰老作用研究[J].黑龙江医药科学,1999,22(4)：36
[58]郭晶,陈非,李丽华,等.中药麦冬对D半乳糖衰老模型大鼠的血液流变性的影响[J].中国微循环,2002,6(4)：246
[59]刘训红,阚毓铭.太子参研究概述[J]时珍国医国药,2000,11(12)：1131-1132
[60]刘维俊,黄光才,叶小青,等.太子参胶囊的药效学研究[J]_中药新药与临床药理,1994,5(3)：51,58.
[61]黄国城,施少捷,郑强.太子参和香菇抗衰老效应的实验研究[J].福建预防医学杂志,1994,3(2)：68.
[62]徐宝林,孙健,杨锋,等.补益药对细胞免疫功能影响的实验研究[J].浙江中医杂志,1996,(5)：219-220.
[63]王家葵,郑军,沈映君,等.太子参总提取物对环磷酰胺处理动物免疫功能和胸腺、脾脏核酸含量的影响[J].中药药理与临床,1996,12(6)：16-18.
[64]王吉吉星,徐绥绪,张国刚,等.太子参化学成分的研究(Ⅳ)[J].中国药物化学杂志,1992,2(3)：65-67.
[65]黄晓洁,颜耀东,杨正娟,那爱华.沙参对免疫功能的影响,沈阳药学院学报,1991,8(3)：204-207
[66]徐宝林,孙健,杨锋,王锦云.补益药对细胞免疫功能影响的实验研究[J]浙江中医杂志,1996,(05)：219-220
[67]郭勇,程晓磊.石斛在恶性肿瘤治疗中的作用[J].浙江中西医结合杂志,2007,17(7)： 454-455
[68]陈云珠,钟鸣.射干药理作用的现代研究进展,中国中医药现代远程教育,2006,4(10)： 27-29
[69]王昊,杨凤琴.10种中药时致病性浅部真菌的抑菌实脸研究.中医杂志,1997,38(7)：431-432
[70]刘春平,王凤荣,南国荣等.中药射干提取物时皮肤碑菌抑菌作用研究中华皮肤科杂志,1998,31(5)：310-311
[71]Oh KB, Kang H, Matsuoka H. Detection of antifungal activity in Belamcanda chinensis by a single-cell bioassay method and isolation of its active compound tectorigenin, Biosci Biotechnol Biochem,2001,65(4):939-942
[72]于军,徐丽华,王云等.射干和马齿览时46株绿脓杆菌体外抑菌试脸的研究.白求恩医科大学学报,2001,27(2)：130-131.
[73]娜杨,孔红,李宜平等.射干的抗病毒实脸研究.中草药,2004,35(3)：306-308
[74]Yamaki K, Kim DH, Ryu N.et.al.Effects of naturally occurring isoflavones on prostaglandin E2 production.Plants Med,2002,68(2):97-100
[75]Ahn KS, Noh EJ, Cha KH.et.al.lnhibitory effects of Irigenin from the rhizomes of & lamcanda chinensis on nitricoxide and prostaglandin E(2) production in murine macrophage RAW 264.7 ceIIs.Life Sci,2006,78(20);2336-2342
[76]Jung SH, Lee YS, Lim SS.et.al.Antioxidant activities of isoflavones from the rhizomes of & lamcanda chinensis on carbon tetrachloride-induced hepatic injury in rats. Arch Pharm Res,2004; 27(2); 184-188
[77]秦民坚,吉文亮,刘俊等.射干中异黄酮成分清除自由基的作用.中草药,2003,34(7)；640
[78]钟鸣,关旭俊,黄炳盛等.中药射干现代研究进展.中药材,2001,24(12)： 904-907
[79]Theien P, seseke F, Ringent RN.et.al.Pharmacological potential of phytoestrogens in the treatment of prostate cancer. Urologe A,2006,45(2):195-201
[80]车景超,辛宁,丰杰.白花蛇舌草药理研究进展安徽农业科学,Journalof Anhui Agricultural Sciences,200735 (20):6162-6167
[81]谭宁华,王双明,杨亚滨等.白花蛇舌草的抗肿瘤活性和初步化学研究[J].天然产物研究与开发,2002,14(5)：33—36.
[82]袁志诚,李巧玉,陈波,等.白花蛇舌草在裸鼠胶质瘤间质化疗的实验研究[J].江苏医药杂志,2003,29(11)：808—810.
[83]于春艳,李薇,刘玉和,等.白花蛇舌草体外对人体肝癌多药耐药细胞Bel-7402 抗肿瘤活性的研究[J].北华大学学报,2004,5(3)：221—223.
[84]于春艳,李薇,刘玉和,等.白花蛇舌草提取物体外抗肿瘤作用及机制研究[J].北华大学学报,2004,5(5)：412—416.
[85]王宇翎,张艳,方明,等.白花蛇舌草总黄酮的免疫调节作用[J].中国药理学通报,2005,21(4)：444—447.
[86]王宇翎,张艳,方明,等.白花蛇舌草总黄酮的抗炎及抗菌作用[J].中国药理学通报,2005,21(3)：348—350.
[87]王桂英,李振彬,石建喜,等.白花蛇舌草对吲哚美辛所致大鼠胃粘膜损伤的保护作用[J].河北中医,2001,23(1)：70—71.
[88]黄景玉,李建平,姜祖光,等.康莱特加白花蛇舌草注射液联合介入治疗晚期原发性肝癌的近期疗效观察[J].实用肿瘤杂志,2002,17(5)：352—353.
[89]唐立明,汪金华,周洪进.静滴白花蛇舌草注射液治疗中晚期食道癌106例临床观察[J].海南医学,2003,14(2)：75.
[90]张琼,张晓亚,庞秀华.白花蛇舌草注射液联合EP方案与单纯EP方案治疗非小细胞肺癌的疗效比较[J].河南职工医学院学报,2001,13(1)：40—41.
[91]李焕荣,李秀荣.中医药抑制肿瘤血管生成抗肿瘤转移的可行性探讨[J]。中西医结合学报,2007,5(4)：378-382
[92]赵旭,李福才,李英慧.等.P53基因突变和STK15基因过度表达与喉癌发生的关系.中华肿瘤杂志.2005,3,27(3)：134-137
[1]Michalides R, van Veelen N, Hart A, et al.Overexpression of cyclinD1 correlates with recurrence in group of forty-seven operable squamous cell carcinomas of the head and nech.Cancer Res,1995,55:975-978.
[2]于锋,董玉礼,祖志将等,喉咽癌手术及综合治疗的临床资料分析,中华耳鼻咽喉科杂志,2003,38(4)：295-299
[3]Tang RZ, Wu XX, Tu GY.The surgical management of carcinoma of the hypopharynx: An analysis of 254 cases. China J Otorhinolaryngol,1997,32 Suppl(Eng):83-88.
[4]屠规益,唐平章,贺永东,等.应用舌骨肌瓣修复部分喉术后缺损.中华耳鼻咽喉科杂志,1996,31：39-42.
[5]屠规益.头颈肿瘤外科中的实证医学.中华耳鼻咽喉科杂志,2000,35：327-330.
[6]郭智,朱永学,嵇庆海,喉咽癌的综合治疗,中国医学文摘耳鼻咽喉科学,2006,21 (6)：363-365
[7]韩德民,于振坤,黄志刚,等.会厌在喉部分切除喉功能重建术中的应用.中华耳鼻咽喉科杂志,2000,35：42-44.
[8]唐平章,屠规益,祁永发,等.喉近全切除术的扩大适应证.中华耳鼻咽喉科杂志,1998,33：175-177.
[9]于锋,董玉礼,韩跃峰,等.喉环上部分切除喉腔成形术.中华耳鼻咽喉科杂志,2001,36：213-215.
[10]Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol,2003,21:320-326.
[11]Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med,2004,350:1937-1944.
[12]Stenson KM, Haraf DJ, Pelzer H, et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy:the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg,2000,126:950-956.
[13]Argiris A, Stenson KM, Brockstein BE, et al. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head andneck cancer. Head Neck,2004,26447-455.
[14]Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer:preliminary results of a European Organization for Research and Treatment of Cancer phase Ⅲ trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst,1996,88:890-899.
[15]Lefebvre JL, Chevalier D, Luboinski B, et al. Is laryngeal preservation(LP)with induction chemotherapy(ICT)safe in the treatment of hypopharyngeal SCC? Final results of the phaseⅢEORTC 24891 trial. J Clin Oncol, ASCO Annual Meeting Proceedings(Post-Meeting Edition),2004,22(14S):Abstr 5531.
[16]Hitt R, Lopez-Pousa A, Rodriguez M, et al. Phaselll study comparing cisplatin and 5 fluorouracil versus cisplatin 5-fluorouracil and paclitaxel asinduction therapy in locally advanced head and neck cancer. Proc Am Soc Clin Oncol,2003,22.
[17]Katori H, Tsukuda M, Ishitoya J, et al. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil(TPF)followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Clin Oncol(RColl Radiol),2005:17:148-152.
[18]Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma:a University of Pennsylvania Phase Ⅱ Trial. J Clin Oncol.2002,20: 3964-3971.
[19]Bonner JA, Giralt J, Harari PM, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck:A phase Ⅲ study of high dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol,2004,22:7078.
[20]Soulieres D, Senzer NN, Vokes EE, et al. Multi center phase Ⅱ study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, inpatients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol, 2004,22:77-85.
[21].Hitt R, Grau J, Lopez-Pousa A, et al. Phase Ⅱ/Ⅲ trial of induction chemotherapy(ICT)with cisplatin/5-fluorouracil(PF)vs. docetaxel(T)plus PF(TPF)followed by chemoradiotherapy(CRT)vs. CRT for unresectable locally advanced head and neck cancer(LAHNC). Proc Am Soc Clin Oncol,2003,22: 496
[22]Ogura JH. Partial laryngopharyngectomy and neck dissection for pyrifom sinus cancer.Laryngoscope,1960,70:1399-1417.
[23]Dumich PS, Pearson BW, Weiland LH. Suitability of near-total laryngopharyngectomy in piriform carcinoma. Arch Otolaryngol,1984 110:664-669.
[24]Hirano M, Kurita S, Tanaka H. Histopathologic study of carcifma ofthe hypopharynx:implications for conservation surgery.Ann Otol Rhinol Laryngol, 1987,96:625-629.
[25]黄建民,栾信庸,潘新良,等.梨状窝内侧壁癌切除与喉功能保留.中华耳鼻咽喉 科杂志,2001,36：254-257.
[26]Harrison DF. Thyroid gland in the management of laryngopharyngeal cancer.Arch Otolaryngol,1973,97:301-302.
[27]Pillsbury HC 3rd, Clark M.A rational for therapy of the NO neck.Laryngoscope, 1997,107:1294-1315.
[28]Spiro RH, Gall O, Shah JP. Selective jugular node dissection in patients with squamous carcinoma of the larynx or pharynx.Am J Surg,1993,166:399-340.
[29]李晓明,宋琦,喉癌喉咽癌的辅助与综合治疗,中国耳鼻咽喉头颈外科,2009 16(10)：555-557
[30]金晶,高黎,徐国镇,等.单纯放疗或单纯手术治疗早期声门型喉癌.中华放射肿瘤学杂志,2005,14：1-5.
[31]Menenhall WM. T3-4 squamous cell carcinoma of the larynxtreated with radiation therapy alone. Semin Radiat Oncol,1998,8:262-269.
[32]Jorgensen K, Godballe C, Hansen O, et al. Cancer of the larynx:treatment results after primary radiotherapy with salvage surgery in a series of 1005 patients. Acta Oncol,2002,41:69-76.
[33]陈建超,王朝晖,李彬,张兵,王少新,李超.保留喉功能喉咽癌的综合治疗.中国耳鼻咽喉头颈外科,2005,12(11)：718-720